Mitoxantrone (N) vs. 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first line therapy in high-risk metastatic breast cancer by von minckwitz, G., Heldemann, E., Souchon, R., Samonigg, H., Hirschmann, W.D., Bodenstein, H., Schindler, A., Schulze, M., Clemens, H., König, M., Scharl, A., Flscher, J.Th, Kaufmann, M.

Get full text